| Long name: |
NARC1 Primary Polyclonal Antibody |
| Also known as: |
NARC1 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
NARC1 |
| Specificity: |
This is a highly specific antibody against NARC1 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
235-285/692 |
| Subcellular location: |
Lysosome, Secreted, Cytoplasm |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human PCSK9/NARC1 |
| Gene ID number: |
255738 |
| Swiss Prot: |
Q8NBP7 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway, Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation, Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner, Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751), May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation, PubMed:17461796, PubMed:18197702, PubMed:22074827), Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways, and promotes their degradation in intracellular acidic compartments (PubMed:18039658), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), very low density lipoprotein receptor (VLDLR), Crucial player in the regulation of plasma cholesterol homeostasis |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
HCHOLA3, LDLCQ1, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, PSEC0052, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, FH3 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
NARC1 |
| Short name: |
NARC1 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
NARC1 (Antibody to) |
| Alternative technique: |
antibodies |